ClinicalTrials.gg
Status unknownNCT03525652Updated May 16, 2018

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

A Phase 1/2 interventional study of Therapeutic vaccine and PD-1 Knockout T Cells in Prostate Cancer, sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University. Status unknown at 2 sites in China. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-05-16.

Sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
336th of 436
30 · median 100
Started
2018
with 21 others
Phase 1/2
52 of 542
30 open now
Registered
71st of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 336th largest by planned enrollment of the 436 interventional ones that give a count, is one of 22 that started in 2018, is one of 52 in phase 1/2, and was the 71st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the safety and efficacy of a therapeutic vaccine in combination with PD-1 knockout T cells in the treatment of advanced prostate cancer.

Read the detailed description

This is a phase 1/2 clinical study investigating the safety and efficacy of a therapeutic vaccine in combination with PD-1 knockout T cells in the treatment of advanced prostate cancer. The therapeutic vaccine is a customized product involving ex vivo treatment of the patient's peripheral blood mononuclear cells with a recombinant fusion protein (PAP-GM-CSF) to activate the expression of the antigen that would activate the immune function to kill cancer cells. The PD-1 knockout engineered T cells are also prepared using patient's T cells in which PD-1 gene will be knocked out using CRISPR Cas9 technology. The therapeutic vaccine and PD-1 knockout T cells will be infused back to the patient in 3 times with a 2-week interval.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Therapeutic vaccine
  • PD-1 knockout
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • confirmed prostate cancer (stage IV, according to NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 2.2017)

      • Evidence of in the soft tissue and/or bone.
      • Progressive androgen independent castrate resistant prostate cancer.
      • Serum PSA ≥ 5.0 ng/mL
      • Estimated ≥ 6 months.
      • Castrate level of testosterone (\< 50 ng/dL) achieved via medical or surgical castration.
      • Adequate hematologic, renal and liver function.

Exclusion criteria

Exclusion Criteria:

    • Presence of known lung, liver, or , malignant pleural effusions, or malignant ascites.

      • Presence of moderate to severe pain treating with opioid analgesics within 21 days prior to registration.
      • score ≥ 2.
      • Any other systemic therapy for prostate cancer (except for medical castration).
      • Participation in previous study using Provenge (Sipuleucel-T) or similar product.
      • Known pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > 50%) or spinal cord compression.
      • Known other than prostate cancer requiring active treatment within 6 months.
      • A requirement for systemic therapy for any reason.
      • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to this product or granulocyte-macrophage colony-stimulating factor.
      • Any infection requiring parenteral antibiotic therapy or causing fever (temp > 100.5°F or > 38.1°C) within 1 week prior to registration.
      • Any medical intervention or other condition which, in the opinion of the Principal Investigator could compromise adherence with study requirements or otherwise compromise the study's objectives.
      • Treatment with any of the following medications or interventions within 28 days of registration:

Systemic use of , External beam radiation therapy or surgery, Use of non-steroidal antiandrogens Dietary and herbal supplements, as well as alternative treatments that have evidence of hormonal and/or anticancer properties (e.g., prostate cancer (PC) -SPES or PC-SPEC) and saw palmetto, Megestrol acetate (Megace®), diethylstilbesterol (DES), or cyproterone acetate, ++Ketoconazole, 5-alpha-reductase inhibitors, Treatment with any other product Treatment with chemotherapy High dose calcitriol [1,25(OH)2Vitamin D] (i.e., > 0.5 mcg/day). Initiation or discontinuation of bisphosphonate therapy

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Therapeutic vaccine

    Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.

    Biological: Therapeutic vaccine

  • Experimental
    Therapeutic vaccine plus PD-1 knockout

    Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.

    Biological: Therapeutic vaccine · Biological: PD-1 Knockout T Cells

  • Active comparator
    PD-1 knockout T cells

    PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.

    Biological: PD-1 Knockout T Cells

Interventions

  • BiologicalTherapeutic vaccine

    The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.

  • BiologicalPD-1 Knockout T Cells

    PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0

    Safety and tolerability of dose of therapeutic vaccine in combination with PD-1 Knockout T cells will be assessed using CTCAE v4.0

    Time frame: 6 months

Secondary outcomes

  1. Response Rate

    Will be assessed according to the revised RECIST guideline v1.1

    Time frame: 6 months

  2. Progression free survival - PFS

    Time from treatment to date of first documented progression or date of death

    Time frame: Up to 12 months

  3. Overall Survival - OS

    Measure the time from the commencement of treatment to death

    Time frame: Death

  4. Peripheral blood circulating tumor DNA

    Circuiting tumor DNA will be measured at baseline and 6 weeks after treatment

    Time frame: 8 weeks

07

Study locations

2 of 2 sites recruiting
  • First Affiliated Hospital of Guangdong Pharmaceutical University
    Guangzhou, Guangdong 510080, China
    Recruiting
  • Professor Size Chen
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Size Chen, MD,PhD · Contact13720956393@139.com · +8613720956393
    • Zhizhou Huang, MSc · Contacthzhizhou@sina.com · +8613268258980
    • Yiguang Lin, MD, PhD · Principal investigator
    • Size Chen, MD, PhD · Principal investigator
    • Micheal Yin, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2018 (actual). Primary completion is estimated for Feb 2021, 36 months after the start.

Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 36 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2018
First posted
May 16, 2018
StartActual
Feb 22, 2018
Primary completionEst.
Feb 22, 2021
CompletionEst.
Aug 30, 2021
Last update
May 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03525652
Lead sponsor
The First Affiliated Hospital of Guangdong Pharmaceutical University
Collaborators
Guangzhou Anjie Biomedical Technology Co., Ltd., University of Technology, Sydney
Responsible party
Size Chen (Professor, The First Affiliated Hospital of Guangdong Pharmaceutical University) — Principal investigator
First posted
May 16, 2018
Start date
Feb 22, 2018
Primary completion
Feb 22, 2021 (estimated)
Completion
Aug 30, 2021 (estimated)
Last update
May 16, 2018

Study contacts

Size Chen, MD, PhD
Contact
13710956393@139.com
+8613710956393
Zhizhou Huang, MSc
Contact
hzhizhou@sina.com
+8613268258980
Size Chen, MD, PhD
principal investigator · The First Affiliated Hospital of Guangdong Pharmaceutical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion